AGIOS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-02-12
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2016-09-30 was 0.00%.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2016-06-30 was 0.00%.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2016-03-31 was 0.00%.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2015-09-30 was 0.00%.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-02-12 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-02-12 | |||
| 2023-12-31 | 0.00% 10-K · filed 2026-02-12 | |||
| 2022-12-31 | 0.00% 10-K · filed 2025-02-13 | |||
| 2021-12-31 | 0.00% 10-K · filed 2024-02-15 | |||
| 2020-12-31 | 0.00% 10-K · filed 2023-02-23 | |||
| 2019-12-31 | 0.00% 10-K · filed 2022-02-24 | |||
| 2018-12-31 | 0.00% 10-K · filed 2021-02-25 | |||
| 2017-12-31 | 0.00% 10-K · filed 2020-02-19 | |||
| 2016-12-31 | 0.00% 10-K · filed 2019-02-14 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2016-11-03 | 0.00% 10-Q · filed 2016-11-03 | ||
| 2016-06-30 | 0.00% 10-Q · filed 2016-08-08 | 0.00% 10-Q · filed 2016-08-08 | ||
| 2016-03-31 | 0.00% 10-Q · filed 2016-05-09 | |||
| 2015-12-31 | 0.00% 10-K · filed 2018-02-14 | |||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-03 | 0.00% 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | 0.00% 10-Q · filed 2016-08-08 | 0.00% 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | 0.00% 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | 0.00% 10-K · filed 2017-02-16 | |||
| 2014-09-30 | 0.00% 10-Q · filed 2015-11-06 | 0.00% 10-Q · filed 2015-11-06 | ||
| 2014-06-30 | 0.00% 10-Q · filed 2015-08-07 | 0.00% 10-Q · filed 2015-08-07 | ||
| 2014-03-31 | 0.00% 10-Q · filed 2015-05-11 | |||
| 2013-12-31 | 0.00% 10-K · filed 2016-02-26 | |||
| 2012-12-31 | 0.00% 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |